|
| |
Tranzyme Pharma Inc.Tranzyme Pharma is a clinical-stage company with a focus on novel products for the treatment of gastrointestinal and metabolic diseases. Tranzyme is developing first-in-class "mechanism-based" therapeutics for Post-operative ileus, gastroparesis, Obesity, and functional GI disorders. The Company recently completed a phase I trial of its lead product, TZP-101, and anticipates on having aq second candidate in the clinic in 2007. Tranzyme's mission is to develop and commercialize both intermally driven products and products developed through partnerships.
| Contact Details: |
| 4819 Emperor Blvd, Suite 400 |
| Durham |
| North Carolina |
| 27703 |
| United States of America |
| Tel: | (919) 313-4760 |
| Fax: | (919) 313-4700 |
| Email: | contact@tranzyme.com |
| WWW: | www.tranzyme.com/
|
|
Loading...
|
Recent Publications by Tranzyme Pharma Inc.: |  |
Efficient parallel synthesis of macrocyclic peptidomimetics.
A new method for solid phase parallel synthesis of chemically and... | 22nd July, 2008
| Tranzyme Pharma Inc. 3001, 12e av. Nord, Sherbrooke, Que., Canada J1H5N4.
| Bioorg Med Chem Lett. 2008 Aug 15;18(16):4731-5. Epub 2008 Jun 28.
DOI Direct Link |
Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids.
Novel, potent small molecule motilin receptor antagonists are described.... | 2nd October, 2007
| Tranzyme Pharma Inc. 3001, 12e av Nord, Sherbrooke, PQ, Canada J1H5N4.
| Bioorg Med Chem Lett. 2007 Aug 1;17(15):4187-90. Epub 2007 May 18.
DOI Direct Link |
(2R)- and (2S)-3-fluoroalanine and their N-methyl derivatives: synthesis and incorporation in peptide scaffolds.
A convergent synthetic methodology has been developed to access both (2S)-... | 1st September, 2007
| Tranzyme Pharma Inc., Institut de pharmacologie de Sherbrooke, 3001 12th
| Org Lett. 2006 Dec 7;8(25):5849-52.
DOI Direct Link |
Discovery of a new class of macrocyclic antagonists to the human motilin receptor.
A novel class of macrocyclic peptidomimetics was identified and optimized... | 16th February, 2007
| Tranzyme Pharma Inc., 3001, 12e Avenue Nord, Sherbrooke, PQ, Canada, J1H
| J Med Chem. 2006 Nov 30;49(24):7190-7.
DOI Direct Link |
Lentiviral vector-based models of amyloid pathology: from cells to animals.
Lentiviral vectors are efficient tools for the introduction of genes into... | 19th January, 2006
| Tranzyme Pharma Inc., 21 Davis Drive, Research Triangle Park, NC 27709,
| Curr Alzheimer Res. 2005 Apr;2(2):239-47.
|
→View more Tranzyme Pharma Inc. research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 283 times since April 2007, the link to the organisation's website has been followed 60 times Recent Search Terms used to find this page: Tranzyme Pharma Inc. Institut De Pharmacologie | Tranzyme Pharma Inc Sherbrooke J1H5N4 TEL | tranzyme pharma inc | tranzyme | @tranzyme.com Sherbrooke PQ | 3-fluoroalanine pharma | 3-fluoroalanine pharma | tranzyme med chem | Tranzyme Pharma Inc. | TZP-101 Synthesis | . Search for more companies in Durham Search for more companies in North Carolina This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Tranzyme Pharma Inc. |
